Tb the Editor:Bladder cancer(BCa)is one of the most common urological malignant tumors.With a worldwide incidence of 573,278 cases in 2020,it ranks eleventh among all tumors.Despite having different approved immune ch...Tb the Editor:Bladder cancer(BCa)is one of the most common urological malignant tumors.With a worldwide incidence of 573,278 cases in 2020,it ranks eleventh among all tumors.Despite having different approved immune checkpoint inhibitors for use among patients with BCa,the response rate to those drugs has remained limited,varying from 20%to 40%.展开更多
基金the National Key Research and Development Program of China(No.SQ2017YFSF090096)the National Natural Science Foundation of China(Nos.81702536,81974099,82070784).
文摘Tb the Editor:Bladder cancer(BCa)is one of the most common urological malignant tumors.With a worldwide incidence of 573,278 cases in 2020,it ranks eleventh among all tumors.Despite having different approved immune checkpoint inhibitors for use among patients with BCa,the response rate to those drugs has remained limited,varying from 20%to 40%.
